cPLA2 mediates the cytotoxicity and apoptosis resulting from tumor necrosis factor in the ischemic kidney during damage to TECs, and inhibition of cPLA2 activity is considered an advantageous strategy to prevent and treat tubulointerstitial inflammation and fibrosis in chronic kidney disease [24, 25]. The gene discussed is PLA2G4A; the disease is urogenital neoplasm.